Introduction
Inflammatory processes are thought to play a major role in the pathogenesis of atherosclerosis and myocardial infarction. During formation of atherosclerotic lesions leukocytes infiltrating the plaque release cytokines that promote local endothelial dysfunction and smooth muscle cell proliferation [8] . Increased systemic markers of inflammation in the clinical state of angina pectoris have been addressed in several studies and have been suggested as predictive markers for a later cardiovascular event [11, 19] .
Inflammation following acute myocardial infarction (AMI) augments myocardial damage and thereby extends post-infarct myocardial dysfunction. Based on these findings, various anti-inflammatory strategies have been proposed in order to downsize myocardial loss (reviewed in [7] ). However, as the inflammatory reaction is also prerequisite for healing and scar formation, suppression of the inflammatory cascade increases the risk of aneurysma formation and ventricular rupture. This could account at least partly for the failure of anti-inflammatory therapy during AMI in clinical practise [5, 20] . As a consequence a better understanding of the inflammatory processes at the site of myocardial infarction would be useful in order to develop further immunmodulatory strategies.
Early attempts made to elucidate the role of pro-inflammatory cytokines at the ischemic site during myocardial infarction included analysis of blood samples obtained from the coronary sinus. However, a major obstacle of coronary sinus sampling is that blood samples are often contaminated by atrial blood [12] . Recently, new technical tools in cardiac catheterization have been introduced, allowing direct blood suction from the culprit coronary artery [14, 16, 23] . Most of the work published has concentrated on the role of sCD40L and IL-6 at the site of infarction.
Concentrations of other inflammatory proteins in the coronary blood flow are still unknown.
The aim of this study was to evaluate levels of sCD40, sCD40L, TNFα and sTNF-RI in the culprit coronary artery and to compare them to systemic concentrations. Blood samples drawn from patients suffering from stable and unstable angina pectoris served as controls.
Materials and Methods
The study protocol was approved by the ethics committee of the University of Vienna Whole blood samples were either retrieved from the femoral artery or directly from the occluded coronary artery by the thrombectomy catheter system into serum tubes (Greiner, Kremsmünster, Austria) as described before [1] . Tubes were centrifuged at 1300g, (4°C, 10min) and serum samples frozen immediately at -80°C.
Angina pectoris patients and blood sample collection
Blood samples from angina pectoris (AP) patients were obtained from patients attending the polyclinic of the Dept. for Cardiolgy, Medical University of Vienna. 
Statistical analysis
Statistical analysis were performed using SPSS software (SPSSInc., Chicago, IL, USA). Data are given as mean ± standard of the mean. Normal distribution was verified using the Kolmogorov-Smirnov test. Paired two-sided T-tests for dependent and unpaired T-tests for independent variables were used calculating significances.
Bonferroni-Holm correction was used to adjust p-values for multiple testings. Pvalues <0.05 were considered statistically significant. 
Results

Characteristics of study patients
Levels of sCD40 and sCD40L
We were able to show that levels of the cleaved, soluble form of CD40 were heightened during AMI when compared to both AP groups (SA: 56.2±6.8pg/mL; UA:
49.5±4.8pg/mL; AMI femoral artery: 60.7±2.6pg/mL; AMI coronary artery:
62.5±4.8pg/mL; Figure 1a , 2a).
Our data are in line with previously published reports on the levels of sCD40L [21] [22] [23] . Serum concentrations increased from 724.3±223.8pg/mL in the SA to 1078.2±592.0pg/mL in the UA group (Figure 1b) . In the AMI group levels of sCD40L were higher in the coronary blood flow (2149.2±160.6) when compared to systemic arterial blood concentrations (2005.4±127.5, Figure 2b ). However, these findings did not reach statistical significance.
Levels of TNFα and sTNF-RI
Levels of TNFα and sTNF-RI are shown in Figure 1c , d and 2c, d. Concentrations of TNFα did not differ between AP and AMI patients. However, sTNF-RI significantly increased during AMI compared to the AP control groups.
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Discussion
The role of inflammation in the pathogenesis of myocardial infarction has been targeted in many studies. However, most of the knowledge regarding local effects/mechanisms of pro-inflammatory cytokines in the myocardium was gained by necropsy studies or animal models. Insight in the inflammatory process in vivo is limited to sparsely clinical studies analyzing blood samples obtained from the coronary sinus.
One major obstacle of the measurement of inflammatory markers from the peripheral circulation is that they may not reflect intra-coronary levels. Moreover, systemic processes can occult measured concentrations and thus may lead to wrong implications [12] . In order to overcome these problems we utilized a X-sizer thrombectomy system to directly obtain blood samples from the culprit coronary artery in our patient series.
Our data corroborate previous reports on the levels of sCD40L in the coronary blood flow during AMI. In addition to these findings, we analyzed concentrations of sCD40, TNFα and sTNF-RI at the site of infarction.
The sCD40/sCD40L system has been shown to be a relevant factor in the pathogenesis of myocardial infarction. sCD40L -an important protein in immunologic function -is released by activated thrombocytes at the site of infarction and thereby bridges the coagulatory and inflammatory system [9] . It has been shown that increased systemic levels of sCD40L during myocardial infarction are useful diagnostic and prognostic markers [22] . Futhermore, the cleaved, soluble form of the sCD40L receptor (sCD40) is able to bind and neutralize sCD40L in the blood circulation. Thereby, increased concentration of sCD40 in our patients during myocardial infarction could be interpreted as a natural regulatory mechanism to prevent an overshoot of sCD40L effects.
Besides sCD40/sCD40L, TNFα seems to be an important cytokine during AMI. It is mainly secreted by resident, intramyocardial macrophages and the myocardium itself To the best of our knowledge this is the first published evidence of intra-coronary levels of sCD40, TNFα and sTNF-RI during myocardial infarction. Furthermore, we were able to confirm published data on levels of sCD40L in the culprit coronary artery. In recent history new therapeutic strategies of myocardial infarction based on an alteration of the inflammatory response have failed. An incomplete knowledge of the inflammatory processes as well as fundamental differences between animal models and disease process in human is made responsible for the disappointing results of these clinical trials [7] . We therefore conclude that a better understanding of the inflammatory cascade is pivotal for developing new anti-inflammatory interventions. Further studies are needed to extend our data on the inflammatory processes taking place in the cardiac milieu during acute myocardial infarction. 
